Plasmalogens, docosahexaenoic acid and neurological disorders.
Farooqui
Akhlaq A
AA
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA. farooqui.1@osu.edu
Ong
Wei-Yi
WY
Horrocks
Lloyd A
LA
D000544:Alzheimer Disease / Q000201:enzymology; D000818:Animals; D001921:Brain / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000378:metabolism* / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000378:metabolism / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007608:Kainic Acid / Q000633:toxicity; D009422:Nervous System Diseases / Q000378:metabolism*; D018901:Peroxisomal Disorders / Q000188:drug therapy / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D054467:Phospholipases A2; D010955:Plasmalogens / Q000378:metabolism*
D004791:Enzyme Inhibitors; D005231:Fatty Acids, Unsaturated; D010955:Plasmalogens; D004281:Docosahexaenoic Acids; D010741:Phospholipases A; D054467:Phospholipases A2; C117522:plasmalogen-selective phospholipase A2; D007608:Kainic Acid